Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,801 to 1,820 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Arm B (Short Term Storage) vs Standard of Care (Long Term Storage): Persistent Organ Dysfunction Combined With Death Measured at Day 28 | 573 of 2,457 549 of 2,462 | 1.0 points -1.3 to 3.4 | 4,919 | NCT01638416 Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial |
| Arm B (Short Term Storage) vs Standard of Care (Long-term Storage): Blood Stream Infection in ICU (Post Randomisation) | 123 of 2,457 88 of 2,462 | 1.4 points 0.3 to 2.6 | 4,919 | NCT01638416 Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial |
| Arm B (Short Term Storage) vs Standard of Care (Long Term Storage): Mortality at Day 28 | 476 of 2,457 463 of 2,462 | 0.6 points -1.6 to 2.8 | 4,919 | NCT01638416 Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial |
| Arm B (Short Term Storage) vs Standard of Care (Long-term Storage): Proportion of Patients Who Suffer at Least One Febrile Non-haemolytic Transfusion Reaction in ICU | 35 of 2,457 39 of 2,462 | -0.2 points -0.9 to 0.5 | 4,919 | NCT01638416 Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial |
| Routine Thermal Management vs Aggressive Thermal Management: Readmission | 135 of 2,447 161 of 2,462 | -1.0 points -2.4 to 0.3 | 4,909 | NCT03111875 Perioperative Hypothermia and Myocardial Injury After Non-cardiac Surgery |
| Interactive Two-way SMS Dialogue vs No SMS Control: Early Neonatal Mortality | 38 of 2,450 28 of 2,447 | 0.4 points -0.2 to 1.1 | 4,897 | NCT04598165 Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support |
| Pre-VAP Diagnostic Stewardship vs VAP Diagnostic Stewardship: deaths from any cause | 1,666 of 4,205 284 of 687 | -1.7 points -5.7 to 2.2 | 4,892 | NCT05176353 Ventilator-associated Pneumonia (VAP) Diagnostic Stewardship Trial |
| Pre-VAP Diagnostic Stewardship vs VAP Diagnostic Stewardship: serious adverse events | 278 of 4,205 34 of 687 | 1.7 points -0.4 to 3.3 | 4,892 | NCT05176353 Ventilator-associated Pneumonia (VAP) Diagnostic Stewardship Trial |
| LAMA vs ICS/LABA: Number of Patients With Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Events | 1,170 of 2,444 1,285 of 2,444 | -4.7 points -7.5 to -1.9 | 4,888 | NCT04172701 A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD) |
| LAMA vs ICS/LABA: Number of Patients With Lung Cancer | 57 of 2,444 53 of 2,444 | 0.2 points -0.7 to 1.0 | 4,888 | NCT04172701 A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD) |
| LAMA vs ICS/LABA: Number of Patients With Tuberculosis (TB) | 56 of 2,444 47 of 2,444 | 0.4 points -0.4 to 1.2 | 4,888 | NCT04172701 A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD) |
| LAMA vs ICS/LABA: Number of Patients With the Event All-cause Death | 51 of 2,444 46 of 2,444 | 0.2 points -0.6 to 1.0 | 4,888 | NCT04172701 A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD) |
| LAMA vs ICS/LABA: Number of Patients With Pneumonia Event | 501 of 2,444 605 of 2,444 | -4.3 points -6.6 to -1.9 | 4,888 | NCT04172701 A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD) |
| LAMA vs ICS/LABA: Number of Patients With Non-tuberculosis Mycobacteria (NTM) Lung Disease | 27 of 2,444 14 of 2,444 | 0.5 points 0.0 to 1.1 | 4,888 | NCT04172701 A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD) |
| LAMA vs ICS/LABA: deaths from any cause | 51 of 2,444 46 of 2,444 | 0.2 points -0.6 to 1.0 | 4,888 | NCT04172701 A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD) |
| LAMA vs ICS/LABA: Number of Patients Who Initiated a Triple Combination Therapy | 383 of 2,444 518 of 2,444 | -5.5 points -7.7 to -3.4 | 4,888 | NCT04172701 A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD) |
| Interactive Two-way SMS Dialogue vs No SMS Control: Neonatal Mortality | 46 of 2,442 37 of 2,442 | 0.4 points -0.4 to 1.1 | 4,884 | NCT04598165 Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support |
| Clopidogrel vs Placebo: Major Hemorrhage Other Than Intracranial Hemorrhage | 17 of 2,432 7 of 2,449 | 0.4 points 0.0 to 0.9 | 4,881 | NCT00991029 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial |
| Clopidogrel vs Placebo: Symptomatic Intracerebral Hemorrhage | 2 of 2,432 2 of 2,449 | 0.0 points -0.2 to 0.2 | 4,881 | NCT00991029 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial |
| Clopidogrel vs Placebo: Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes | 121 of 2,432 160 of 2,449 | -1.6 points -2.9 to -0.2 | 4,881 | NCT00991029 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=91
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01638416-140a3d5a",
"title": "Arm B (Short Term Storage) vs Standard of Care (Long Term Storage): Persistent Organ Dysfunction Combined With Death Measured at Day 28",
"summary": "573 of 2457 against 549 of 2462; risk difference 1.0 points, 95% interval -1.3 to 3.4; NCT01638416, Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial",
"record": "/library/comparisons/NCT01638416-140a3d5a",
"nct_id": "NCT01638416",
"kind": "outcome",
"participants": 4919,
"risk_difference": {
"value": 0.010221793731135742,
"lower": -0.01323152314105007,
"upper": 0.03366384400379389
},
"group_1": "573 of 2,457",
"group_2": "549 of 2,462",
"difference": "1.0 points",
"interval": "-1.3 to 3.4",
"trial_title": "Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial"
},
{
"id": "NCT01638416-4be6e3df",
"title": "Arm B (Short Term Storage) vs Standard of Care (Long-term Storage): Blood Stream Infection in ICU (Post Randomisation)",
"summary": "123 of 2457 against 88 of 2462; risk difference 1.4 points, 95% interval 0.3 to 2.6; NCT01638416, Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial",
"record": "/library/comparisons/NCT01638416-4be6e3df",
"nct_id": "NCT01638416",
"kind": "outcome",
"participants": 4919,
"risk_difference": {
"value": 0.014317751929449736,
"lower": 0.002983365741377293,
"upper": 0.025783062233339808
},
"group_1": "123 of 2,457",
"group_2": "88 of 2,462",
"difference": "1.4 points",
"interval": "0.3 to 2.6",
"trial_title": "Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=92",
"request_id": "OmI1NkFgPNahVtTt"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant